If you should know one thing about us, know this: we will not rest until we leave no person living with HIV behind. Until the 38 million people living with HIV is down to zero, we will continue searching for new ways to limit the impact of HIV.
Born out of a partnership between GSK and Pfizer in 2009, with Shionogi joining in 2012, at ViiV Healthcare we are determined to help end the HIV epidemic. Our one focused goal unites our employees located across the globe, with their expertise in research, manufacturing, policy and more, all guided by our mission to be here until HIV isn’t.
Our product portfolio consists of 17 prescription medicines, in the HIV space. This is only the beginning as our research centre in Branford, Connecticut, USA, the world’s only HIV-dedicated facility, which is utterly focused on finding new innovative medicines to help improve the lives of people living with HIV.
Also searching to find major breakthroughs against HIV is our industry-defining partnership with the HIV Cure Centre at the University of North Carolina. Part of a unique public-private collaboration ‘Qura Therapeutics’, we have been combining resources and expertise to accelerate novel breakthroughs and maximise the chance of finding a HIV cure.
Alongside our novel approach to R&D, improving access to medicines is just as important in delivering results for our patients. At ViiV Healthcare we are dedicated to widening access to ensure those who need our medicines can receive them. Collaborations with organisations such as IAS, CHAI and MPP enable our medicines to make the greatest possible impact in countries around the world. As an example, our voluntary licence agreements allow generic manufacturers to develop paediatric formulations of our medicines where 99% of children living with HIV live. We are committed to working ever closer with our partners through continued access initiatives.
To accelerate the HIV response, we put significant focus on community initiatives to strengthen local healthcare services for people living with HIV. Through our Positive Action programmes, which back over 300 projects worldwide, our work with local communities aim to deliver long-lasting impacts on groups such as women and children. We seek to enhance local expertise and resources that build towards global goals, as well as our own dedicated mission of leaving no person living with HIV behind.